A 35-year-old nulliparous woman with a giant uterine myoma is described. During the past three years she had developed a intramural myoma and a subserous myoma. Although the lesions were excised, both reappeared and were treated with GnRH analogues for 6 months.
A 35-year-old nulliparous woman with a giant uterine myoma is described. During the past three years she had developed a intramural myoma and a subserous myoma. Although the lesions were excised, both reappeared and were treated with GnRH analogues for 6 months. The subserous myoma was then endoscopically excised, leaving the intramural myoma in situ. The remaining myoma grew uncontrollably and open surgery with possible hysterectomy was proposed.
A physical examination revealed a displaced and enlarged uterus, matching a four-month pregnancy. As ultrasound studies showed an heterogeneous myoma measuring 15 cm in diameter, with poor uterine visualization, a T2-weighted MRI was performed. A conservative approach with uterine repair using a reabsorbable mesh and fibrin glue was planned.
This is a new uterine muscle repair that includes a Vicryl mesh, fibrin glue, and collagen when required. The mesh may act as a support for the initial steps of repair and avoid unnecessary movements that may break the suture line. The fibrin glue and collagen shorten tissue healing processes. Benefits for both the patient and surgeon include a repair that prevents uterine ruptures after myomectomy or other surgeries. This approach may allow tension-free sutures and reduce the effects of uterine contractions on sutures and dead spaces.
Control MRI T2 Mode: The images obtained three months after the surgery have demonstrated a correct myometral repair.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
Figure 12
Figure 13
Figure 14
Figure 15
Figure 16
Figure 17
Figure 18
Figure 19
Figure 20
Figure 21
Figure 22
Figure 23
Figure 24
José M Palacios Jaraquemada MD, Ph.D
Av. Corrientes 5087 4º A
C1414AJD Ciudad de Buenos Aires, Argentina
jpalacios@ciudad.com.ar
Unlocking placenta accreta spectrum with single-cell gene targets
April 18th 2024Discover how cutting-edge single-cell RNA sequencing unveils molecular insights into placenta accreta spectrum disorders, potentially revolutionizing diagnostics and treatments for this life-threatening pregnancy complication.
Read More
Understanding VTE and bleeding risks in gynecologic noncancer surgery
April 15th 2024Delve into the nuanced risks of venous thromboembolism and major bleeding post-gynecologic noncancer surgery, exploring procedure-specific variations and the implications for thromboprophylaxis strategies.
Read More
Maternal history linked to uterine fibroid risk in Black women
April 11th 2024Delve into the findings of a recent study revealing the heightened risk of developing uterine fibroids among Black women with a maternal history of the condition, shedding light on crucial implications for patient care and advocacy.
Read More